CD95 / APO-1 / TNFRSF6 / FAS Antibody ( FITC ) (Cytokine)

CD95 / APO-1 / TNFRSF6 / FAS Antibody Datasheet

CD95 / APO-1 / TNFRSF6 / FAS Antibody Product Information

• Immunogen: Recombinant Human CD95 / APO-1 / TNFRSF6 / FAS protein (Catalog#10217-H08H)
• Reagents: FITC-conjugated mouse monoclonal antibody
• Clone ID: 10
• Ig Type: Mouse IgG1
• Concentration: 10 μl/Test, 0.1 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD95 / APO-1 / TNFRSF6 / FAS (rh CD95 / APO-1 / TNFRSF6 / FAS; Catalog#10217-H08H; NP_000034.1; Met 1-Asn 173) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

CD95 / APO-1 / TNFRSF6 / FAS Antibody Usage Guide

• Specificity: Human CD95 / APO-1 / TNFRSF6 / FAS
• Flow Cytometry:
  

  Profile of anti-Human FAS (CD95) reactivity on Jurkat cells analyzed by flow cytometry.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

CD95 / APO-1 / TNFRSF6 / FAS Antibody Background

Fas, also known as APO-1, CD95 and TNFRSF6, is a member of the tumor necrosis factor (TNF) / nerve growth factor (NGF) receptor superfamily. Fas is highly expressed on the surface of a number of cell types including epithelial cells, hepatocytes, activated mature lymphocytes and other tumor cells. This receptor contains a death domain and has been shown to play a central role in the physiological regulation of programmed cell death (PCD, apoptosis) upon ligation of Fas ligand (Fas-L). This Fas receptor has been reported to be involved in the activation of NF-kappaB, MAPK3/ERK1, MAPK8/JNK, and the alternate pathways for CTL-mediated cytotoxicity. Accordingly, this protein is implicated in the pathogenesis of various malignancies and diseases of the immune system. Multiple Fas isoforms are derived from alternative spliced transcript variants, and among which, a soluble form lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoforms.

References

1. Brunner,T. et al., 1995, Nature. 373: 441-444.
2. Hirata, H. et al., 1998, J. Exp. Med. 187: 587-600.
3. Suda, T. et al., 1993, Cell. 75: 1169-1178.
4. Milhas,D. et al., 2005, J. Biol. Chem. 280:19836-19842.
5. Cascino, I. et al., 1995, J.Immunol. 154: 2706-2713.
6. Mary, M. et al., 2001, J. Biol. Chem. 276: 4964-4971.